RLAY Q2 2023 Earnings — Relay Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RLAYRelay Therapeutics, Inc.

$2B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$119,000-67.4% YoY

Gross Profit

-$88M-74018.5% margin

Operating Income

-$106M-89117.6% margin

Net Income

-$99M-82777.3% margin

EPS (Diluted)

$-0.81

QoQ Revenue Growth

-47.3%

Cash Flow

Operating Cash Flow

-$69M

Free Cash Flow

-$70M

Stock-Based Comp.

$23M

Balance Sheet

Total Assets

$962M

Total Liabilities

$152M

Stockholders' Equity

$810M

Cash & Equivalents

$146M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$119,000	$365,000	-67.4%
Gross Profit	-$88M	-$60M	-46.4%
Operating Income	-$106M	-$78M	-36.3%
Net Income	-$99M	-$77M	-28.3%